Introducing the Cosmos Connect from Control Bionics
April 28, 2022
We’re constantly working towards our mission of making life-changing connections which brought us to our latest product offering, the Cosmos Connect.
Menu
We’re constantly working towards our mission of making life-changing connections which brought us to our latest product offering, the Cosmos Connect.
Control Bionics (ASX:CBL) is all set to launch its NeuroNode Trilogy technology in Japan in partnership with major assistive technology distributor, Double R&D Co Ltd.
Highlighted in an article by Kalkine Media, Control Bionics achieved a year of strong growth and is forging ahead in the current year to level up its momentum.
According to the recent paper published by biomedical engineering student Lester Lo at RMIT University, eye gaze combined with EMG switching outperformed traditional eye gaze AAC systems.
Featured in a writeup by Kalkine Media, Control Bionics is proud to report a 34% sales revenue growth in the December quarter.
This year, Control Bionics was honored to be included in the annual listing of 20 companies that are at the forefront of providing Medtech Year End Special Solutions and impacting the industry.
This week, Control Bionics CEO Rob Wong sat down with Bulls N’ Bears host Matt Birney to discuss the company’s innovative technology and market growth. Listen to the full interview.
Control Bionics continues to expand our leadership team with new Head of Sales – Australia, Annette Curry. Annette brings years of experience as a nurse practitioner, sales and marketing leader.
Control Bionics is excited to announce the expansion of their management team with Vice President – North America, Todd Tyler.
USA
745 Center Street, Suite 303
Milford OH 45150
AUSTRALIA
697 Burke Road, Level 5, Suite 5.01
Camberwell VIC 3124
CANADA
Bridges Canada
2123 McCowan Road
Scarborough, Ontario M1S 3Y6
JAPAN
©2012-2023 Control Bionics, Inc. All Rights Reserved
